RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMI

02.12.2021 - RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMIHigh Body Mass Index and obesity are known risk factors for H. Pylori eradication treatment failure; Newly published data in GastroHep ...

Related Keywords

Michigan ,United States ,London ,City Of ,United Kingdom ,Israel ,Americans ,American ,Redhill Biopharma ,June Almenoff ,John Yung Chong Kao ,London Stock Exchange ,Division Of Gastroenterology ,National Cancer Institute ,World Health Organization ,Nasdaq ,Redhill Biopharma Ltd ,University Of Michigan ,Company Annual Report On Form ,Exchange Commission ,End Results Program ,Company Expanded Access Program ,Low Dose Rifabutin Triple Therapy ,High Body Mass ,Internal Medicine ,Chief Medical Officer ,Hill Biopharma ,Tubulointerstitial Nephritis ,Private Securities Litigation Reform Act ,Expanded Access Program ,Annual Report ,Systematic Review ,Cell Biochem ,Cancer Institute ,Florence Consensus Report ,London Stock ,